Silicon Canals
No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us
No Result
View All Result
Silicon Canals
No Result
View All Result

Belgium’s Bone Therapeutics secures €16M loan from EIB to develop new cell therapy-based orthopaedic treatments

Editorial team by Editorial team
July 5, 2021
in (Crowd)funding, Health & Medtech, News, Startups
Bone Therapeutics CEO

Image credits: Bone Therapeutics

30
SHARES
LinkedInTwitterWhatsAppFacebook
Read this article in:

A few years back, the concept of altering genes to treat disease was considered science fiction. However, it is now a reality. Thanks to technological advancements, numerous other cutting-edge approaches are reshaping how we treat and cure diseases. 

Cell therapy is one such approach that involves injecting new cells into a patient’s body to replace or repair damaged tissue to treat a disease. According to the report, a total of 1342 active cell-based therapy clinical trials have been identified and characterised based on cell type, target indication, and trial phase.

Nowadays, various medical organisations use cell therapies that are clinically approved. Based in Gosselies, Belgium, Bone Therapeutics is a biopharmaceutical company focused on innovative cell therapy products to treat bone diseases. 

Secured €16M

Recently, the company secured a €16M loan from the European Investment Bank (EIB) to accelerate the clinical development of ALLOB, Bone Therapeutics’ scalable allogeneic cell therapy platform.

- Partner content -
Atlas HXM EOR Employee of Record
How EOR is becoming a crucial tool in 2023
EOR gains importance as companies digitise and hire globally. Learn from industry leaders...Show More
EOR gains importance as companies digitise and hire globally. Learn from industry leaders using EOR with Atlas HXM.Show Less
Read more

Further, EIB will also support and prepare Bone Therapeutics’ lead product, viscosupplement JTA-004, for future regulatory approval and commercialisation. 

What is ALLOB?

ALLOB is an allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. It is currently in two Phase I/IIA proof-of-concept trials for the treatment of delayed-union fractures and spinal fusion procedures. 

The patient recruitment is expected to complete in the first half of 2022 and the results in the second half. 

What is JTA-004?

JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable, which is currently in phase III development for treating osteoarthritic pain in the knee. 

JTA-004 consists of a unique patented mix of plasma proteins, hyaluronic acid – a natural component of knee synovial fluid, and a fast-acting analgesic. It intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation.

The Belgian company plans to submit a marketing authorisation application to European regulatory authorities in the first half of 2022. Additionally, the company continues to engage with potential partners to develop and commercialise JTA-004 in Europe, the US, and Asia.

Loan conditions

The EIB will be disbursing the loan in two tranches of €8M each, subject to conditions precedent.

The first €8M will be available upon approval of the issuance of associated warrants by Bone Therapeutics’ General Meetings before the end of August 2021. 

The next €8M will be released when specific clinical and commercial milestones have been achieved.

“The loan facility will be in the form of a senior loan, repayable to the EIB in a single payment five years following the disbursement of each of the two tranches. The loan carries a fixed interest of 2 per cent per year paid annually and a 3% capitalized interest,” says the press release.

Diversified cell and biologic therapies portfolio

Founded in 2006, Bone Therapeutics has an extensive portfolio of cell and biological therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions. 

“Bone Therapeutics is building towards a very important set of milestones, including moving towards potential regulatory approval and commercialisation of therapy for over 250 million patients, as well as continuing with the clinical development of its allogeneic cell therapy platform ALLOB. In addition, we are building on our success in orthopedics and moving our formidable MSC capabilities to target wider indications. The support of a major European financial institution such as the EIB will be an additional important component to this activity,” says Jean-Luc Vandebroek, Chief Financial Officer, Bone Therapeutics. 

“This financing committed by the EIB will allow Bone Therapeutics to further advance the clinical development of its lead product candidates JTA-004 and ALLOB, further accelerating paths to approval and commercialisation,” he adds. 

 - Partner content -
How to succesfully outsource…
How to succesfully outsource…
...your recruitment or product development with our curated community partners!
...your recruitment or product development with our curated community partners! Show Less
Read more
Tags: Belgian startupfundingHealth-& Medtech
Share2Tweet8SendShare12

Partner with us | Download Media Kit

Thank you for visiting Silicon Canals! If you want to partner with us, look at our options.

Featured | Tech Events

Current Month

november, 2023

Silicon Canals | Jobs

Breaking news from Amsterdam | Partner

Invest-NL secures €350M in guarantees for Dutch sustainable ventures through InvestEU partnership: Know more

Looking for a job in Amsterdam? These unicorns are hiring currently hiring

Amsterdam’s hypeal.com raises €188K to reshape the way digital assets are utilised

Partner content | Work with us

Amsterdam-based startups that raised funding in September; some are hiring right now

Amsterdam’s Framer secures €25.5M to scale its no-code website building platform

Product Spotlight: Fairphone 5 with co-founder Miquel Ballester

  • About Silicon Canals
  • Partner with Silicon Canals
  • Impressum
  • Contact us
  • Sign up for our newsletter!
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Community partners
    • Amsterdam
    • Rise by Techleap.nl
    • EOR handbook by Atlas HXM
    • Guest Contributions
    • Business Wire
    • Sign up for our newsletter!
  • Global Jobs
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Contribute your content
    • Team
    • About us
  • Partner with us

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

X
X